GS
JBIO

GTS Securities’s Jade Biosciences JBIO Stock Holding History

GTS Securities’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-718
Closed -$63.1K – 1234
2025
Q1 		$63.1K Buy
718
+430
+149% +$37.8K ﹤0.01% 1188
2024
Q4 		$26.7K Buy
+288
New +$24.8K ﹤0.01% 1192
2024
Q3 		– Sell
-591
Closed -$34.3K – 4064
2024
Q2 		$34.3K Buy
+591
New +$392K ﹤0.01% 3742

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

GTS Securities's JBIO Position: Q2 2025 in Review

GTS Securities sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 718 shares — an estimated $63.1K sold.

GTS Securities first reported a position in JBIO in Q2 2024 and held it in 3 quarters. The position peaked at $63.1K in Q1 2025. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • GTS Securities reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 718 Jade Biosciences shares in Q2 2025, an estimated $63.1K.
  • GTS Securities first reported a position in Jade Biosciences in Q2 2024 and held it in 3 quarters.
  • GTS Securities's Jade Biosciences position peaked at $63.1K in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.